{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:33:42Z","timestamp":1794108822960,"version":"4.8.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010798","name":"Sunway University","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/SKK11\/SYUC\/03\/3"],"award-info":[{"award-number":["FRGS\/1\/2018\/SKK11\/SYUC\/03\/3"]}],"id":[{"id":"10.13039\/501100010798","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.peptides.2020.170443","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T11:03:54Z","timestamp":1604747034000},"page":"170443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease"],"prefix":"10.1016","volume":"136","author":[{"given":"Salima","family":"Lalani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai Ti","family":"Gew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chit Laa","family":"Poh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(13)70342-6","article-title":"Hand, foot, and mouth disease in China, 2008\u201312: an epidemiological study","volume":"14","author":"Xing","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.peptides.2020.170443_bib0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.peptides.2020.170443_bib0020","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"issue":"6","key":"10.1016\/j.peptides.2020.170443_bib0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/np50024a015","article-title":"An investigation of the antiviral activity of Podophyllum peltatum","volume":"45","author":"Bedows","year":"1982","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.peptides.2020.170443_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.antiviral.2017.01.013","article-title":"Oxymatrine provides protection against Coxsackievirus B3-induced myocarditis in BALB\/c mice","volume":"141","author":"Jiang","year":"2017","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.peptides.2020.170443_bib0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/v12020184","article-title":"Flavonoids as antiviral agents for Enterovirus A71 (EV-A71)","volume":"12","author":"Lalani","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.peptides.2020.170443_bib0040","doi-asserted-by":"crossref","DOI":"10.1590\/0001-3765201920190105","article-title":"The role of natural products in modern drug discovery","volume":"91","author":"Calixto","year":"2019","journal-title":"An. Acad. Bras. Cienc."},{"key":"10.1016\/j.peptides.2020.170443_bib0045","unstructured":"A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection, https:\/\/ClinicalTrials.gov\/show\/NCT03376321."},{"key":"10.1016\/j.peptides.2020.170443_bib0050","unstructured":"Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers, https:\/\/ClinicalTrials.gov\/show\/NCT02478463."},{"key":"10.1016\/j.peptides.2020.170443_bib0055","unstructured":"Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy, https:\/\/ClinicalTrials.gov\/show\/NCT02489461."},{"key":"10.1016\/j.peptides.2020.170443_bib0060","unstructured":"Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients, https:\/\/ClinicalTrials.gov\/show\/NCT02362503."},{"issue":"12","key":"10.1016\/j.peptides.2020.170443_bib0065","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.4155\/fmc.12.94","article-title":"Therapeutic peptides","volume":"4","author":"Albericio","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.peptides.2020.170443_bib0070","unstructured":"Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients with HBeAg Negative HBV\/HDV Co-infection, https:\/\/ClinicalTrials.gov\/show\/NCT02637999."},{"key":"10.1016\/j.peptides.2020.170443_bib0075","unstructured":"Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers, https:\/\/ClinicalTrials.gov\/show\/NCT02612506."},{"key":"10.1016\/j.peptides.2020.170443_bib0080","unstructured":"Safety and Efficacy of ADAPTAVIR\u2019s Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs), https:\/\/ClinicalTrials.gov\/show\/NCT00951743."},{"key":"10.1016\/j.peptides.2020.170443_bib0085","unstructured":"Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress, https:\/\/ClinicalTrials.gov\/show\/NCT04311697."},{"issue":"18","key":"10.1016\/j.peptides.2020.170443_bib0090","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00018-019-03138-w","article-title":"Antiviral peptides as promising therapeutic drugs","volume":"76","author":"Boas","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0095","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1128\/JVI.01840-06","article-title":"Antiviral peptides targeting the West Nile virus envelope protein","volume":"81","author":"Bai","year":"2007","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0100","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.peptides.2020.170443_bib0105","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/00002030-200405210-00007","article-title":"Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations","volume":"18","author":"Clotet","year":"2004","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17425247.2017.1360863","article-title":"Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections","volume":"15","author":"Lembo","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"issue":"8","key":"10.1016\/j.peptides.2020.170443_bib0115","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1517\/13543784.9.8.1723","article-title":"Cationic antimicrobial peptides: towards clinical applications","volume":"9","author":"Hancock","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.peptides.2020.170443_bib0120","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fimmu.2019.01366","article-title":"Peptide antiviral strategies as an alternative to treat lower respiratory viral infections","volume":"10","author":"Nyanguile","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.peptides.2020.170443_bib0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nchembio.1982","article-title":"Molecular mechanism of respiratory syncytial virus fusion inhibitors","volume":"12","author":"Battles","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00170-x","article-title":"Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor","volume":"8","author":"Roymans","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2020.170443_bib0135","unstructured":"R. Jordan, K. Stray, F. Anderson, M. Perron, R. Mackman, M. Miller, H. Mo, E. Svarovskaia, R. Martin, Y. Xin, Analysis of GS-5806 resistance emergence in human healthy adult subjects experimentally infected with respiratory syncytial virus (RSV), Infectious Diseases Society of America, p. 1189."},{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0140","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02241-16","article-title":"A short double-stapled peptide inhibits respiratory syncytial virus entry and spreading","volume":"61","author":"Gaillard","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.peptides.2020.170443_bib0145","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1128\/JVI.02139-12","article-title":"Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture","volume":"87","author":"Sadeghipour","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.peptides.2020.170443_bib0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.antiviral.2015.10.006","article-title":"Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16","volume":"124","author":"Kelly","year":"2015","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.peptides.2020.170443_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034589","article-title":"Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1","volume":"7","author":"Tan","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.peptides.2020.170443_bib0160","doi-asserted-by":"crossref","first-page":"e02251","DOI":"10.1128\/JVI.02251-17","article-title":"Fibronectin facilitates enterovirus 71 infection by mediating viral entry","volume":"92","author":"He","year":"2018","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead-and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.peptides.2020.170443_bib0170","unstructured":"S. Penades, J. Rojo, M. Martin-Lomas, Nanoparticles, Google Patents, 2008."},{"key":"10.1016\/j.peptides.2020.170443_bib0175","article-title":"An Update-Prolonging the action of protein and peptide drugs","author":"Cao","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"12","key":"10.1016\/j.peptides.2020.170443_bib0180","first-page":"763","article-title":"Enhancing the oral bioavailability of peptide drugs by using chemical modification and other approaches","volume":"4","author":"Yin","year":"2014","journal-title":"Med. Chem."},{"issue":"10","key":"10.1016\/j.peptides.2020.170443_bib0185","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic\u2013pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.peptides.2020.170443_bib0190","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/psc.1388","article-title":"Further studies on the antiviral activity of alloferon and its analogues","volume":"17","author":"Kuczer","year":"2011","journal-title":"J. Pept. Sci."},{"issue":"5","key":"10.1016\/j.peptides.2020.170443_bib0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijantimicag.2005.02.011","article-title":"Inhibitory activity of bovine lactoferrin against echovirus induced programmed cell death in vitro","volume":"25","author":"Tinari","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.peptides.2020.170443_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170402","article-title":"Peptides to combat viral infectious diseases","author":"Al-Azzam","year":"2020","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.peptides.2020.170443_bib0205","first-page":"3919","article-title":"The antimicrobial peptides and their potential clinical applications","volume":"11","author":"Lei","year":"2019","journal-title":"Am. J. Transl. Res."},{"issue":"8","key":"10.1016\/j.peptides.2020.170443_bib0210","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/v11080704","article-title":"Human antimicrobial peptides as therapeutics for viral infections","volume":"11","author":"Ahmed","year":"2019","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.peptides.2020.170443_bib0215","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12275-016-6376-1","article-title":"Inhibitory effects of bee venom and its components against viruses in vitro and in vivo","volume":"54","author":"Uddin","year":"2016","journal-title":"J. Microbiol."},{"issue":"3","key":"10.1016\/j.peptides.2020.170443_bib0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4149\/av_2018_222","article-title":"Induction and antiviral activity of human \u03b2-defensin 3 in intestinal cells with picornavirus infection","volume":"62","author":"Chen","year":"2018","journal-title":"Acta Virol."},{"issue":"6","key":"10.1016\/j.peptides.2020.170443_bib0225","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000442588","article-title":"Recombinant mouse \u03b2-defensin 3 protects against coxsackievirus B3-induced myocarditis in mice","volume":"58","author":"Jiang","year":"2015","journal-title":"Intervirology"},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2005.03.005","article-title":"Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells","volume":"67","author":"Weng","year":"2005","journal-title":"Antiviral Res."},{"issue":"2-3","key":"10.1016\/j.peptides.2020.170443_bib0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0166-3542(95)00840-3","article-title":"Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells","volume":"29","author":"Marchetti","year":"1996","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.peptides.2020.170443_bib0240","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1046\/j.1365-2672.2003.02071.x","article-title":"The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures","volume":"95","author":"McCann","year":"2003","journal-title":"J. Appl. Microbiol."},{"issue":"2","key":"10.1016\/j.peptides.2020.170443_bib0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0166-3542(02)00069-4","article-title":"Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides","volume":"55","author":"Berkhout","year":"2002","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.peptides.2020.170443_bib0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2003.09.001","article-title":"Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate","volume":"61","author":"Jenssen","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.peptides.2020.170443_bib0255","series-title":"Protease Inhibitors as Potential Antiviral Agents for the Treatment of Picornaviral Infections","first-page":"197","author":"Wang","year":"1999"},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0260","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.virol.2009.12.017","article-title":"Targeting enteroviral 2A protease by a 16-mer synthetic peptide: inhibition of 2Apro-induced apoptosis in a stable Tet-on HeLa cell line","volume":"399","author":"Maghsoudi","year":"2010","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bsheal.2019.02.005","article-title":"Surveillance, epidemiology, and pathogen spectrum of hand, foot, and mouth disease in mainland of China from 2008 to 2017","volume":"1","author":"Ji","year":"2019","journal-title":"Biosaf. Health"},{"issue":"8","key":"10.1016\/j.peptides.2020.170443_bib0270","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/343809","article-title":"Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro","volume":"186","author":"Lin","year":"2002","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.peptides.2020.170443_bib0275","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.vaccine.2007.12.013","article-title":"Recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonatal mice from a lethal challenge with enterovirus type 71","volume":"26","author":"Chen","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-020-0615-9","article-title":"Cellular receptors for enterovirus A71","volume":"27","author":"Kobayashi","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"28","key":"10.1016\/j.peptides.2020.170443_bib0285","doi-asserted-by":"crossref","first-page":"25406","DOI":"10.1074\/jbc.M110.201103","article-title":"Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo","volume":"286","author":"Tiwari","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0290","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/JVI.02226-12","article-title":"Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.peptides.2020.170443_bib0295","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/jac\/dks304","article-title":"Blocking human enterovirus 71 replication by targeting viral 2A protease","volume":"67","author":"Falah","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0300","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.virusres.2012.08.016","article-title":"Antiviral protection against enterovirus 71 mediated by autophagy induction following FLICE-inhibitory protein inactivation","volume":"169","author":"Won","year":"2012","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.peptides.2020.170443_bib0305","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tips.2013.11.006","article-title":"Current progress in antiviral strategies","volume":"35","author":"Lou","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.peptides.2020.170443_bib0310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","article-title":"Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials","volume":"106","author":"Aguirre","year":"2016","journal-title":"Adv. Drug Del. Rev."},{"issue":"28","key":"10.1016\/j.peptides.2020.170443_bib0315","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.2174\/138161210793292555","article-title":"Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization","volume":"16","author":"Gentilucci","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.peptides.2020.170443_bib0320","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1073\/pnas.1711837115","article-title":"Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB","author":"Garton","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.peptides.2020.170443_bib0325","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1128\/JVI.02979-14","article-title":"Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: implications for the development of entry-based antiviral therapy","volume":"89","author":"Jaishankar","year":"2015","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.peptides.2020.170443_bib0330","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0167-7799(00)88999-4","article-title":"Recent developments in retro peptides and proteins\u2014an ongoing topochemical exploration","volume":"13","author":"Chorev","year":"1995","journal-title":"Trends Biotechnol."},{"issue":"1","key":"10.1016\/j.peptides.2020.170443_bib0335","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/088922200309601","article-title":"A retro-inverso miniantibody with anti-HIV activity","volume":"16","author":"Levi","year":"2000","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0340","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","article-title":"Strategies to improve plasma half life time of peptide and protein drugs","volume":"30","author":"Werle","year":"2006","journal-title":"Amino Acids"},{"issue":"48","key":"10.1016\/j.peptides.2020.170443_bib0345","doi-asserted-by":"crossref","first-page":"14130","DOI":"10.1021\/bi035643g","article-title":"Structure-based design of an indolicidin peptide analogue with increased protease stability","volume":"42","author":"Rozek","year":"2003","journal-title":"Biochemistry"},{"issue":"6362","key":"10.1016\/j.peptides.2020.170443_bib0350","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1126\/science.aan0516","article-title":"Potent peptidic fusion inhibitors of influenza virus","volume":"358","author":"Kadam","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.peptides.2020.170443_bib0355","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0360","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.peptides.2020.170443_bib0365","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1073\/pnas.1002713107","article-title":"Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic","author":"Bird","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.peptides.2020.170443_bib0370","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/clpt.2009.159","article-title":"Orally administered glucagon\u2010like peptide\u20101 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects","volume":"86","author":"Steinert","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.peptides.2020.170443_bib0375","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.clinthera.2011.05.088","article-title":"Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects","volume":"33","author":"Castelli","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.peptides.2020.170443_bib0380","unstructured":"Oral Insulin: A Comparison with Subcutaneous Regular Human Insulin in Patients with Type 2 Diabetes, https:\/\/ClinicalTrials.gov\/show\/NCT00982254."},{"key":"10.1016\/j.peptides.2020.170443_bib0385","first-page":"12","article-title":"Oral peptide delivery: technology landscape and current status","volume":"59","author":"Hassani","year":"2015","journal-title":"Drug Deliv."},{"issue":"1-2","key":"10.1016\/j.peptides.2020.170443_bib0390","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijpharm.2018.02.038","article-title":"Lipid-based nanosuspensions for oral delivery of peptides, a critical review","volume":"541","author":"Dumont","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"24","key":"10.1016\/j.peptides.2020.170443_bib0395","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1128\/JVI.01678-06","article-title":"Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells","volume":"80","author":"Jones","year":"2006","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.peptides.2020.170443_bib0400","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.peptides.2020.170443_bib0405","first-page":"1","article-title":"Materials for oral delivery of proteins and peptides","author":"Brown","year":"2019","journal-title":"Nat. Rev. Mater."},{"issue":"5","key":"10.1016\/j.peptides.2020.170443_bib0410","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1208\/s12249-019-1325-z","article-title":"Nanoparticles: oral delivery for protein and peptide drugs","volume":"20","author":"Cao","year":"2019","journal-title":"AAPS PharmSciTech"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978120301923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978120301923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:46:20Z","timestamp":1778535980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978120301923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":82,"alternative-id":["S0196978120301923"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2020.170443","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2020.170443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"170443"}}